Second-line chemotherapy with cabzitaxel and prednisolone (CP) in castratation-resistant prostate cancer (CRPC): Tolerability and efficacy—A U.K. institution experience.
Amir H Montazeri
No relevant relationships to disclose
Chinnamani Eswarvee
No relevant relationships to disclose
Helen Wong
No relevant relationships to disclose
Zafar I Malik
Research Funding - Janssen-Cilag; Sanofi